Business Insider

Mylan posts quarterly profit compared to year-earlier loss

imageStock Markets2 hours ago (Aug 06, 2020 06:55AM ET)

(C) Reuters. Logo of Mylan Laboratories, a company primarily engaged in the commercialization of generic drugs is pictured in Merignac near Bordeaux

(Reuters) – Mylan NV (O:MYL) reported a second-quarter profit on Thursday, helped in part by strong sales of its newly launched products such as asthma drug Wixela.

The drugmaker reported net earnings of $39.4 million, or 8 cents per share, in the three months ended June 30, compared to a loss of $168.5 million, or 33 cents per share, a year earlier.

Total revenue of the company, whose merger with Pfizer Inc’s (N:PFE) off-patent branded drugs unit has been delayed by the pandemic, fell to $2.73 billion from $2.85 billion.

Mylan posts quarterly profit compared to year-earlier loss

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles

Back to top button

Get the daily email that makes reading the news actually enjoyable. Stay informed and entertained, for free.

Your information is secure and your privacy is protected. By opting in you agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!